IL-17 antagonistic antibodies

US9765140B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Franco E. Di Padova · Birsfelden, CH
• Hermann Gram · Weil am Rhein, DE
• Hans Hofstetter · Riehen, CH
• Margit Jeschke · Basel, CH
• Jean-Michel Rene Rondeau · Rixheim, FR
• Wim Van Den Berg · Molenhoek, NL

Key dates

• Filing date: Feb 18, 2015
• Grant date: Sep 19, 2017
• Expiry date: Feb 21, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An Interleukin-17 (IL-17) binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.